Abbott has launched TriClip transcatheter edge-to-edge repair (TEER) system in India for the treatment of tricuspid regurgitation (TR), a condition caused by a leaking tricuspid valve.

The minimally invasive device is delivered through a vein in the leg and works by clipping together portions of the valve leaflets to restore proper blood flow without the need for open-heart surgery.

The technology builds on Abbott’s MitraClip platform used for mitral valve repair but features a specialised delivery system designed for the right side of the heart.

The company said patients treated with TriClip generally require only a one-day hospital stay before discharge.

Tricuspid regurgitation occurs when the tricuspid valve fails to close properly, causing blood to flow backward within the heart. The condition can lead to symptoms such as fatigue, breathlessness, atrial fibrillation, and heart failure if left untreated. Abbott noted that TR is increasingly being recognised in India, particularly among elderly patients and those with rheumatic heart disease, pulmonary hypertension, or other cardiac disorders.

Sudheer Mirajkar, Country Manager for Abbott’s Structural Heart business in India, said the introduction of TriClip expands treatment options for patients who are unsuitable for surgery and could significantly improve quality of life and clinical outcomes.